/RVPH
RVPH Stock - Reviva Pharmaceuticals Holdings, Inc.
Healthcare|BiotechnologyNASDAQ
$0.60+2.41%
+$0.01 (+2.41%) • Dec 19
67
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.48
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.66
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for RVPH
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.59 – $0.60
TARGET (TP)$0.69
STOP LOSS$0.55
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-0.03
52W High$2.17
52W Low$0.25
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | $-724,740 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-30,798,889 | $-39,503,636 | $-24,306,608 | $-10,104,513 | $-2,434,651 |
| Net Income | $-29,918,802 | $-39,260,837 | $-24,339,292 | $-8,521,876 | $-3,783,388 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-0.90 | $-1.65 | $-1.45 | $-0.58 | $-1.24 |
Company Overview
Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is RP5063, which is in Phase III clinical trials for the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity. The company is headquartered in Cupertino, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
3
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
3 Bullish0 Neutral/Bearish
Price Targets
$10
Average Target
↑ 1625.4% Upside
Now
$2
Low
$10
Average
$17
High
Based on 3 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| September 29th 2025 | Chardan Capital Markets | Initiation | Buy | $2 |
| September 20th 2023 | ROTH MKM | Initiation | Buy | $12 |
| June 8th 2023 | The Benchmark Company | Initiation | Speculative Buy | $17 |
Earnings History & Surprises
RVPHBeat Rate
61%
Last 18 quarters
Avg Surprise
+4.8%
EPS vs Estimate
Beats / Misses
11/5
2 met exactly
Latest EPS
$-0.06
Q4 2025
EPS Surprise History
Q2 24
0.0%
$-0.35vs$-0.35
Q2 24
+10.7%
$-0.25vs$-0.28
Q3 24
+7.1%
$-0.26vs$-0.28
Q4 24
-8.7%
$-0.25vs$-0.23
Q1 25
+31.8%
$-0.15vs$-0.22
Q2 25
+38.1%
$-0.13vs$-0.21
Q3 25
+20.0%
$-0.12vs$-0.15
Q4 25
+45.5%
$-0.06vs$-0.11
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 30, 2026 | $-0.06 | — | — | — |
Q4 2025 | Nov 13, 2025 | $-0.11 | $-0.06 | +45.5% | ✓ BEAT |
Q3 2025 | Aug 14, 2025 | $-0.15 | $-0.12 | +20.0% | ✓ BEAT |
Q2 2025 | May 15, 2025 | $-0.21 | $-0.13 | +38.1% | ✓ BEAT |
Q1 2025 | Mar 31, 2025 | $-0.22 | $-0.15 | +31.8% | ✓ BEAT |
Q4 2024 | Nov 14, 2024 | $-0.23 | $-0.25 | -8.7% | ✗ MISS |
Q3 2024 | Aug 14, 2024 | $-0.28 | $-0.26 | +7.1% | ✓ BEAT |
Q2 2024 | May 14, 2024 | $-0.28 | $-0.25 | +10.7% | ✓ BEAT |
Q2 2024 | Apr 15, 2024 | $-0.35 | $-0.35 | 0.0% | = MET |
Q4 2023 | Nov 14, 2023 | $-0.35 | $-0.44 | -25.7% | ✗ MISS |
Q3 2023 | Aug 14, 2023 | $-0.29 | $-0.55 | -89.7% | ✗ MISS |
Q2 2023 | May 15, 2023 | $-0.36 | $-0.30 | +16.7% | ✓ BEAT |
Q1 2023 | Mar 30, 2023 | $-0.23 | $-0.38 | -65.2% | ✗ MISS |
Q4 2022 | Nov 14, 2022 | $-0.30 | $-0.18 | +40.0% | ✓ BEAT |
Q3 2022 | Aug 15, 2022 | $-0.31 | $-0.29 | +6.5% | ✓ BEAT |
Q2 2022 | May 16, 2022 | $-0.28 | $-0.40 | -42.9% | ✗ MISS |
Q1 2022 | Mar 15, 2022 | $-0.24 | $-0.24 | 0.0% | = MET |
Q4 2021 | Nov 15, 2021 | $-0.25 | $-0.12 | +52.0% | ✓ BEAT |
Q3 2021 | Aug 16, 2021 | $-0.24 | $-0.12 | +50.0% | ✓ BEAT |
Q2 2021 | May 17, 2021 | — | $-0.10 | — | — |
Latest News
D. Boral Capital Maintains Buy on Reviva Pharmaceuticals, Maintains $2 Price Target
📈 PositiveBenzinga•Nov 19, 2025, 01:43 PM•Also:
Reviva Pharmaceuticals Q3 EPS $(0.06) Beats $(0.10) Estimate
📈 PositiveBenzinga•Nov 13, 2025, 09:34 PM
Reviva To Present At Neuroscience 2025 On Nov. 15
➖ NeutralBenzinga•Nov 12, 2025, 01:07 PM
Reviva Granted European Patent Covering Use Of Brilaroxazine In Treatment Of Pulmonary Fibrosis
📈 PositiveBenzinga•Nov 10, 2025, 01:06 PM
D. Boral Capital Maintains Buy on Reviva Pharmaceuticals, Maintains $2 Price Target
📈 PositiveBenzinga•Oct 28, 2025, 06:12 PM
Reviva Pharma To Present Negative Symptom Data For Brilaroxazine In Schizophrenia From Long-Term Open-Label Extension Trial In Clinically Stable Schizophrenia Patients At CNS Summit 2025
➖ NeutralBenzinga•Oct 28, 2025, 12:21 PM
HC Wainwright & Co. Maintains Buy on Reviva Pharmaceuticals, Lowers Price Target to $4
📈 PositiveBenzinga•Oct 27, 2025, 10:35 AM
Chardan Capital Initiates Coverage On Reviva Pharmaceuticals with Buy Rating, Announces Price Target of $2
📈 PositiveBenzinga•Sep 29, 2025, 11:22 AM
Reviva Pharmaceuticals Holdings shares are trading lower after the company announced the pricing of a $9 million offering of 27 million common shares together with 27 million Series E Warrants and 27 million Series F Warrants at $0.335 per share.
📉 NegativeBenzinga•Sep 19, 2025, 12:57 PM
D. Boral Capital Maintains Buy on Reviva Pharmaceuticals, Lowers Price Target to $2
➖ NeutralBenzinga•Sep 19, 2025, 11:09 AM
Reported Earlier, Reviva Pharmaceuticals Prices $9M Offering Of 27M Common Shares Together With 27M Series E Warrants And 27M Series F Warrants At $0.335 Per Share
📉 NegativeBenzinga•Sep 19, 2025, 04:55 AM
Reviva Pharmaceuticals Holdings shares are trading lower after the company announced a proposed public offering.
📉 NegativeBenzinga•Sep 18, 2025, 08:19 PM
Reviva Pharmaceuticals announces proposed public offering
➖ NeutralSeeking Alpha•Sep 18, 2025, 08:18 PM
Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering, Size Not Disclosed
➖ NeutralBenzinga•Sep 18, 2025, 08:07 PM
Benchmark Maintains Speculative Buy on Reviva Pharmaceuticals, Lowers Price Target to $7
➖ NeutralBenzinga•Sep 15, 2025, 01:01 PM
Roth Capital Reiterates Buy on Reviva Pharmaceuticals, Lowers Price Target to $3
➖ NeutralBenzinga•Aug 18, 2025, 05:52 PM
D. Boral Capital Maintains Buy on Reviva Pharmaceuticals, Maintains $3 Price Target
📈 PositiveBenzinga•Aug 18, 2025, 11:27 AM
Reviva Pharmaceuticals holdings announces pricing of $10M public offering
➖ NeutralSeeking Alpha•Jun 26, 2025, 12:56 PM
Reviva Pharmaceuticals announces public offering; shares down nearly 15%
📉 NegativeSeeking Alpha•Jun 25, 2025, 08:28 PM
Frequently Asked Questions about RVPH
What is RVPH's current stock price?
Reviva Pharmaceuticals Holdings, Inc. (RVPH) is currently trading at $0.60 per share. The stock has moved +2.41% today.
What is the analyst price target for RVPH?
No analyst price targets are currently available for this stock.
What sector is Reviva Pharmaceuticals Holdings, Inc. in?
Reviva Pharmaceuticals Holdings, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is RVPH's market cap?
Reviva Pharmaceuticals Holdings, Inc. has a market capitalization of $0.04 billion, making it a small-cap company.
Does RVPH pay dividends?
No, Reviva Pharmaceuticals Holdings, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorANVS
Annovis Bio, Inc.
$3.65
Mkt Cap: $0.1B
ATNM
Actinium Pharmaceuticals, Inc.
$1.69
Mkt Cap: $0.1B
BCAB
BioAtla, Inc.
$0.75
Mkt Cap: $0.0B
BTAI
BioXcel Therapeutics, Inc.
$1.73
Mkt Cap: $0.0B
CELU
Celularity Inc.
$1.45
Mkt Cap: $0.0B
EVAX
Evaxion Biotech A/S
$4.70
Mkt Cap: $0.0B
FGEN
FibroGen, Inc.
$8.60
Mkt Cap: $0.0B
PDSB
PDS Biotechnology Corporation
$0.89
Mkt Cap: $0.0B
PYPD
PolyPid Ltd.
$3.97
Mkt Cap: $0.0B
TVRD
Tvardi Therapeutics, Inc.
$3.98
Mkt Cap: $0.0B
Explore stocks similar to RVPH for comparison